hold
price close busi septemb
biomed devic servic
come around posit lt valu
upgrad buy pt
upgrad zimmer biomet hold buy believ compani
approach apex turnaround cusp multi-year cycl
acceler top-lin growth translat increment leverag opportun
beyond view invest improv suppli chain new
product cadenc cultur chang account commercial-centr focu
taken hold indic encourag result upbeat commentari
compani final posit go offens
look see myriad opportun upsid current consensu
estim driven primarili new product flow core knee/spine/set busi unit
what expect manag continu guid conserv
believ top-lin out-performance lead addit leverag opportun exit
suppli chain improv work inventori channel
annual invest sale market
experi acceler growth even modest y/i
least support zbh current valuat howev expect like scenario
on-going march improv investor sentiment multipl expans
continu drive stock higher net net share trade discount
large-cap med-tech peer believ opportun time begin build
posit increas rate buy pt
strateg cultur chang start take root month new
manag helm believ stori get better strategy/
cultur chang begin percol becom visibl remind
new ceo came board late focus bulk attent
resolv qualiti suppli issu suppli issu larg solv quality/
regulatori track acceler pace new product launch
improv sale forc morale/execut point increas confid
manag respect approach near-term goal growth in-lin
market six month earli well confid eventu eclips market
growth improv execut new product cycl
see upsid rosa rosa launch slowli roll
expect momentum build support broader
offens commerci push believ capabl place system
system us would repres
top-lin growth system alon despit
success grow instal base unit us dilig
suggest signific pent-up demand loyalist estim
us knee share vs offer signific user base sell
new product offer multipl shot goal price mix estim
lost us market share sinc bmet acquisit announc
math cloud contribut price/mix clear
suppli issu limit new product flow lack robot caus signific
annual share loss continu next page
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
continu previou page said consist reiter
expect new product play import part compani return
sustain revenu earn growth agre past month
compani significantli bolster product portfolio materi launch
knee persona partial persona cementless persona revis
extrem sidu stemless shoulder comprehens
basepl system well robot rosa knee rosa spine
product fill materi gap portfolio view
launch cementless knee particularli import fill key competit
gap vs come price premium complementari rosa robot
applic bottom line set first time nearli
four year commerci channel equip least product
standpoint go offens target competit account well upsel
exist custom premium technolog expect launch impact
fundament momentum also investor sentiment market check
survey regard new product launch begin screen favor exit
margin let get ahead lt opportun view
turnaround top line set multi-year cadenc earn
leverag exit simpli put histor oper juggernaut
fallout bmet acquisit subsequ manufacturing/
commerci challeng weigh ebitda margin tune
said oper focu begin shift simpli
invest stabil suppli drive effici improv cost structur
organ leverag take time new inventori work channel
sales/market invest annual show product howev think
green shoot like come current model
y/i improv om expand expect
compani immedi rebound gm om seen
expect deliv consist leverag growth year beyond
lastli manufactur qualiti call manag reiter
confid progress made remedi effort state remain
track two-year turnaround plan qualiti program expect
place set anoth fda audit decis
importantli manufacturing/qu issu longer impact abil suppli key
product delay key product launch
broad large-cap med-tech group current trade median price-to-earnings multipl
valu zimmer discount large-cap med-tech group
given lower top-lin growth rel show stori previous use
discount rate valuat analysi howev believ
appropri go forward given increas confid time
potenti new product introduct sum adjust pt
base price-to-earnings multipl appli pro-forma ep
figur matrix discount rate impli share price target
buy hold target price septemb
biomed devic servic
comp pe multipl price metric use price-to-earnings valuat analysisbroad large-cap medic devic price-to-earnings multipl adjust pro-forma zimmer biomet hold
chang estim
made follow chang estim
figur summari chang estim
zimmer biomet
zimmer world-wide leader design develop manufactur market
reconstruct spinal implant trauma relat orthoped surgic product
compani coverag discuss report
buy hold target price septemb
biomed devic servic
except ep newold newold newold revenu gross operatin ebitda net figur incom statement
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
buy hold target price septemb
biomed devic servic
zimmer biomet incom statementcanaccord genuiti kyle except per share good devic gener asset op incom chg chg amort stk incom minor incom ep ep ep chg share gener oper rate adjust growth ep ex growth ep ex compani document canaccord genuiti estim figur pro forma revenu build
buy hold target price septemb
biomed devic servic
zimmer biomet revenu buildcanaccord genuiti kyle euro yen fx impact impact fx growth growth zimmer biomet hold
